Rhythm Pharmaceuticals is advancing its oral obesity drug bivamelagon to Phase III studies after it significantly reduced ...

Rhythm Pharmaceuticals received a wave of price target hikes on Wednesday after releasing encouraging Phase 2 results for ...

Rhythm Pharmaceuticals' experimental drug helped patients with a rare form of obesity caused by brain damage cut weight in a small study, the drugmaker said on Monday, sending its shares 24% higher in ...

Rhythm Pharmaceuticals’ push to move obesity patients from jabs to tabs has stayed on beat. | Rhythm Pharmaceuticals’ push to ...

Rhythm Pharmaceuticals has captured Wall Street's attention following impressive Phase 2 results for its experimental obesity ...

Rhythm Pharmaceuticals' potential first-in-class HO drug, strong pipeline, and limited competition offer blockbuster potential. Click to read why RYTM is a Buy.

Rhythm's bivamelagon cut BMI and hunger scores in Phase 2 trial for hypothalamic obesity, prompting plans to discuss Phase 3 ...

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the ...

Rhythm said results of the recent trial were also consistent with BMI reductions achieved with setmelanotide therapy in similar patient populations in past trials. Setmelanotide, an existing ...

Rhythm Pharmaceuticals plans to request an End-of-Phase 2 meeting with the FDA to discuss advancing bivamelagon for acquired hypothalamic obesity. What adverse events were reported during the trial?

Rhythm’s lead asset, IMCIVREE® (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the U.S. Food and Drug Administration (FDA) to reduce excess ...

Rhythm Pharmaceuticals' experimental drug helped patients with a rare form of obesity caused by brain damage cut weight in a small study, the drugmaker said on Monday, sending its shares 24% ...